The Peptide Addict library is organized by compound. Each profile carries a visible scorecard across six dimensions and separates what is known, unknown, and overstated. New profiles are added on a weekly cadence.
Currently published
- BPC-157: What Human Evidence Actually Exists? — the most popular recovery peptide on the internet, and a case study in how popularity can outrun evidence.
Coming soon
The full launch library includes canonical pages for:
- GLP-1 class — semaglutide, tirzepatide, retatrutide
- Recovery class — TB-500, GHK-Cu
- Growth hormone secretagogues — CJC-1295, ipamorelin
- Longevity class — MOTS-c, epitalon
- Sexual health — PT-141
- Cognitive class — semax, selank
Each profile is written using the Peptide Addict four-lens framework. See our methodology for the evaluation approach, and the Beginner's Guide for the foundational framing.
What a The Peptide Addict profile contains
Every profile includes:
- Scorecard — evidence strength, human data depth, safety certainty, regulatory clarity, access complexity, and hype gap
- What it is — plain-English description of the compound
- Why people use it — honest account of the usage landscape
- Mechanism in brief — what the biology suggests
- Human evidence — what actually exists, not what's implied
- Preclinical evidence — animal and in-vitro data with appropriate caveats
- Safety and side effects — known, unknown, and what contamination implies for gray-market sourcing
- Legal and access reality — where this compound sits in the US regulatory landscape
- Hype vs reality — the gap, named directly
- Key unanswered questions — what would change our view
- Sources — what we read, what we relied on
Profiles are living documents. We update them as evidence emerges.